Glioblastoma multiforme epidemiology and demographics

Jump to navigation Jump to search

Glioblastoma multiforme Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Glioblastoma multiforme from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Glioblastoma multiforme epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Glioblastoma multiforme epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Glioblastoma multiforme epidemiology and demographics

CDC on Glioblastoma multiforme epidemiology and demographics

Glioblastoma multiforme epidemiology and demographics in the news

Blogs on Glioblastoma multiforme epidemiology and demographics

Directions to Hospitals Treating Glioblastoma multiforme

Risk calculators and risk factors for Glioblastoma multiforme epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Marjan Khan M.B.B.S.[2]

Overview

Glioblastoma multiforme is the the most common adult primary intracranial neoplasm worldwide. The incidence of glioblastoma multiforme is estimated to be 3.2 cases per 100,000 individuals worldwide. Glioblastoma multiforme is a common disease that tends to affect older adults and the elderly population. The median age at diagnosis is 64 years. Males are more commonly affected with glioblastoma multiforme than females. The male to female ratio is approximately 1.5 to 1. Glioblastoma multiforme usually affects individuals of the Caucasian race.

Epidemiology and Demographics

Incidence

  • Glioblastoma multiforme is the the most common adult primary intracranial neoplasm worldwide.[1]
  • The incidence of glioblastoma multiforme is estimated to be 3.2 cases per 100,000 individuals worldwide.[2]
  • This is highest IR among brain and CNS tumors with malignant behavior. [3]
  • Incidence is highest in the northeast and lowest in the south-central region of US.[4]

Mortality rate

  • Glioblastoma multiforme is the most malignant astrocytoma.[5]
  • The median overall survival (OS) is approximately 12 months and a 5‐year OS of 4.8%‐5.4%.

Age

  • Glioblastoma multiforme is a common disease that tends to affect older adults and the elderly population.
  • The median age at diagnosis is 64 years.[2]
  • The incidence increases with age peaking at 75–84 years and drops after 85 years.[4]
  • Glioblastoma multiforme is uncommon in children.

Gender

  • Males are more commonly affected with glioblastoma multiforme than females.
  • The male to female ratio is approximately 1.6 to 1.[1]
  • Marital status is an independent prognostic factor for GBM.[6]
  • One observational study shows protective effect of marriage on GBM survival especially in male older than 60 years of age.[6]

Race

  • Incidence of GBM is 2.0 times higher in Caucasians compared to Africans and Afro-Americans. [7]
  • There is lower incidence in Asians and American Indians.[8]

References

  1. 1.0 1.1 Epidemiology of glioblastoma multiforme. Dr Dylan Kurda and Dr Frank Gaillard et al. Radiopaedia 2015. http://radiopaedia.org/articles/glioblastoma
  2. 2.0 2.1 Thakkar JP, Dolecek TA, Horbinski C, Ostrom QT, Lightner DD, Barnholtz-Sloan JS; et al. (2014). "Epidemiologic and molecular prognostic review of glioblastoma". Cancer Epidemiol Biomarkers Prev. 23 (10): 1985–96. doi:10.1158/1055-9965.EPI-14-0275. PMC 4185005. PMID 25053711.
  3. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (August 2007). "The 2007 WHO classification of tumours of the central nervous system". Acta Neuropathol. 114 (2): 97–109. doi:10.1007/s00401-007-0243-4. PMC 1929165. PMID 17618441.
  4. 4.0 4.1 Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y, Stroup NE, Kruchko C, Barnholtz-Sloan JS (November 2013). "CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010". Neuro-oncology. 15 Suppl 2: ii1–56. doi:10.1093/neuonc/not151. PMC 3798196. PMID 24137015.
  5. Yabroff KR, Harlan L, Zeruto C, Abrams J, Mann B (March 2012). "Patterns of care and survival for patients with glioblastoma multiforme diagnosed during 2006". Neuro-oncology. 14 (3): 351–9. doi:10.1093/neuonc/nor218. PMC 3280803. PMID 22241797.
  6. 6.0 6.1 Xie JC, Yang S, Liu XY, Zhao YX (August 2018). "Effect of marital status on survival in glioblastoma multiforme by demographics, education, economic factors, and insurance status". Cancer Med. 7 (8): 3722–3742. doi:10.1002/cam4.1688. PMC 6089174. PMID 30009575.
  7. Sturm D, Bender S, Jones DT, Lichter P, Grill J, Becher O, Hawkins C, Majewski J, Jones C, Costello JF, Iavarone A, Aldape K, Brennan CW, Jabado N, Pfister SM (February 2014). "Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge". Nat. Rev. Cancer. 14 (2): 92–107. doi:10.1038/nrc3655. PMC 4003223. PMID 24457416.
  8. Jiang L, Fang X, Bao Y, Zhou JY, Shen XY, Ding MH, Chen Y, Hu GH, Lu YC (2013). "Association between the XRCC1 polymorphisms and glioma risk: a meta-analysis of case-control studies". PLoS ONE. 8 (1): e55597. doi:10.1371/journal.pone.0055597. PMC 3559473. PMID 23383237.


Template:WikiDoc Sources